David Dornan - 01 Apr 2026 Form 4 Insider Report for Whitehawk Therapeutics, Inc. (WHWK)

Reporting relationship: Chief Scientific Officer
Issuer ticker: WHWK
Reported as of: 01 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Apr 2026, 18:22:38 UTC
Prior SEC filing: 04 Mar 2025
Source filing: View source filing
Reporting owner signature: /s/ Stephen Rodin, as Attorney-in-Fact

Key filing fact

David Dornan filed Form 4 for Whitehawk Therapeutics, Inc. (WHWK) on 03 Apr 2026.

Key facts

This page summarizes David Dornan's Form 4 filing for Whitehawk Therapeutics, Inc. (WHWK).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Apr 2026, 18:22.

Change

Previous filing in this sequence was filed on 04 Mar 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001821353 Primary reporting owner

Dornan David

Relationship: Chief Scientific Officer
Address: C/O WHITEHAWK THERAPEUTICS, INC., 2 HEADQUARTERS PLAZA, EAST BUILDING, 11T, MORRISTOWN
Signature: /s/ Stephen Rodin, as Attorney-in-Fact
Signature date: 03 Apr 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

WHWK transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +282,340
Change %
Price: $0.000000^*
Shares after: 282,340
Date: 01 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 282,340
Exercise price: $3.54
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the Option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 1, 2026.